for Improved Patient Care
Pixyl.Neuro is a cutting-edge medical technology that harnesses the power of advanced artificial intelligence to detect anomalies and changes in brain MR images for neuroinflammatory and neurodegenerative disorders.
It has been rigorously tested and certified as a CE-marked class IIa medical device by our notifying body TUV-Rheinland, ensuring unparalleled safety and efficacy for our users.
Our proprietary AI algorithms, combined with our lightning-fast computing infrastructure, enable analysis to be completed in less than five minutes, and with on minimal MR protocols.
This provides doctors with rapid diagnostic support, allowing for more efficient and effective treatment plans.
We are proud to be laureate of the French Society for Radiology Data Challenge, attesting to the quality and efficacy of our technology.
At Pixyl, we are driven by a passion to transform healthcare and improve patient outcomes through innovation and collaboration. We believe that to achieve our vision, we must work closely with experts from a diverse range of fields, including medical professionals, researchers, and technologists.
By collaborating with our partners, we are able to harness a broad range of expertise and insights to push the boundaries of what’s possible in medical technology. We are dedicated to fostering a culture of collaboration and a shared commitment to our vision of transforming healthcare.
It is an honor for us to work alongside experts who share our values and dedication to improving the lives of patients and their families. Together, we will continue to deliver innovative solutions and drive progress and innovation in healthcare delivery.
GRENOBLE, FRANCE (Nov 20, 2023) – Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro™, the next-generation AI software for brain MRI analysis that recently demonstrated
We are honored to be selected as one of the most innovative companies in France by Le Point ! We are grateful for this recognition